TL;DR
Get everyday helpers delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
Austrian company Med-El has launched the TICI Unico, which places the microphone, processor and battery beneath the skin, and says it has European regulatory approval. Four commercial implantations took place on the announcement morning. A company-reported 30-patient trial found hearing performance comparable to its conventional implants, but the device is not yet available in the United States.
Austrian medical-device company Med-El has launched the TICI Unico, a cochlear implant with its microphone, sound processor and rechargeable battery implanted beneath the skin, and says the device has European regulatory approval. Four commercial implantations were performed on the morning of the launch, the company said, making the device an option for recipients seeking to hear without wearing an external processor. It is not yet available in the United States.
Conventional cochlear implants use a unit worn behind the ear to capture and process sound, then transmit signals through the scalp to an electrode array in the cochlea. Med-El’s new system moves the microphone and other main components inside the body. The company says this can let users hear without putting on or removing an external sound processor, including while sleeping or swimming. Those are potential benefits of the design, not a guarantee of suitability or results for every recipient.
The 20-gram implant comprises four connected components. A microphone sits about 6 millimeters beneath the scalp and links to a postage-stamp-size stimulator containing sound-processing hardware and a rechargeable lithium-ion battery. A coil enables data transfer and charging; another lead connects to an electrode array in the cochlea, like those used in Med-El’s conventional implants. A car-key-size charger called the GoPod attaches magnetically over the coil.
The battery is not replaceable. Med-El says it is designed to provide up to 40 hours of use per charge, with charging taking about one to one-and-a-half hours. The company says performance data indicates the device should maintain at least 24 hours of use per charge for a minimum of 15 years. That is a company projection, not a report of 15 years of observed use.
Hearing Without an External Processor
Moving all components beneath the skin addresses a practical limitation of conventional cochlear implants: users must manage a visible external processor that can press, slip, or be lost, and is not suited to every activity. A fully implanted system could make hearing available without putting the processor on each day, including during sleep or water-based activities, according to Med-El’s description.
The design also adds a trade-off. Because the battery cannot be replaced, its longevity and the process for maintaining the implant matter to users over the long term. The reported battery-life figures are performance expectations from the company; the first commercial recipients will provide experience with the device outside the trial setting over time.
For people considering implantation, performance and daily convenience both matter. The available evidence described in the source report suggests hearing performance comparable to Med-El’s conventional implants, but the studies are limited and do not establish how the device will perform for all candidates or in all listening conditions.
As an affiliate, we earn on qualifying purchases.
From Early Ambition to Launch
Cochlear implants have been used since the 1980s to bypass damaged parts of the ear in people with severe-to-profound hearing loss. They convert sound into electrical signals that stimulate the auditory nerve through electrodes placed in the cochlea. Most established systems rely on an external microphone and processor to pick up and encode sound.
Med-El chief executive Ingeborg Hochmair said the ambition to make a fully implanted device dates to the 1970s, but that microphone and battery technology held it back. The company says development of the TICI Unico took more than 15 years. Bringing the microphone beneath the scalp was the largest engineering challenge, according to project leader Gerhard Mark, because sound travels differently through tissue. Mark did not disclose details of the technical solution.
Before the commercial launch, a six-patient feasibility study led by Philippe Lefebvre of University Hospital of Liège was published in Communications Medicine last year. The launch report also describes a company-reported clinical trial involving 30 patients. Med-El says that trial found performance comparable to its conventional implants. The source report says data from other studies cited by Hochmair was still awaiting peer review.
“For the first time, all components of a cochlear implant, including the microphone, are implanted beneath the skin.”
— Ingeborg Hochmair, Med-El chief executive
med-el TICI Unico cochlear implant
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Long-Term Results Still Developing
The launch and four initial commercial implantations are confirmed by Med-El’s announcement as reported by IEEE Spectrum, but broader real-world results are not yet available. The source report does not give detailed trial outcomes, such as the measures used to compare hearing performance, the length of follow-up, or how results varied among the 30 participants.
It is also unclear how the implanted microphone performs across different environments and whether sound quality or everyday usability differs from an external microphone for particular users. The company says it took years of research to address sound transmission through tissue, but has not released technical details. Battery life beyond the measured period remains a projection, and the source does not specify how a failing or depleted non-replaceable battery would be handled.
Regulatory approval is reported for Europe, but the article does not identify the approving authority or describe which patients qualify. The device’s U.S. regulatory status, application timeline and expected availability have not been provided.
waterproof cochlear implant with internal microphone
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Availability and Follow-Up Data
The immediate next step is commercial use in Europe following regulatory approval, with the first four recipients beginning that experience after the launch-day procedures. Med-El has not announced a U.S. release date in the source report, so potential U.S. recipients will need to wait for further regulatory and company updates.
More published clinical evidence will help clarify how the implant compares with conventional systems across a wider group of users and over longer follow-up. The pending peer review of additional studies cited by Hochmair may provide further information, while experience with the commercial recipients will be needed to assess durability, charging routines and the claimed battery life. The company has not provided dates for those disclosures.
As an affiliate, we earn on qualifying purchases.
Key Questions
What is the TICI Unico?
It is Med-El’s cochlear implant designed to place the microphone, sound processor, rechargeable battery and other main components beneath the skin. It connects to an electrode array in the cochlea.
Has the device reached patients?
Yes. Med-El said four commercial implantations were carried out on the morning the device was launched. The source report also says a volunteer received it in 2024 as part of a clinical trial.
How long does the battery last?
Med-El says the battery is designed to provide up to 40 hours of use per charge, with charging taking about one to one-and-a-half hours. The company projects at least 24 hours of use per charge for a minimum of 15 years, based on performance data; that duration has not yet been demonstrated through 15 years of use.
Is the TICI Unico available in the United States?
No. The source report says the device has European regulatory approval but is not yet available in the United States. No U.S. launch date is given.
Does it perform as well as a conventional cochlear implant?
Med-El says a clinical trial involving 30 patients found comparable hearing performance to its conventional implants. A separate six-patient feasibility study also reported results suggesting comparable performance. These findings are early evidence and do not establish outcomes for every recipient.
Source: hn
Fall Picks
fall essentials
As an affiliate, we earn on qualifying purchases.
